id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-306072-tfvt6sjq	Ong, Sean Wei Xiang	Safety and potential efficacy of cyclooxygenase‐2 inhibitors in coronavirus disease 2019	2020-07-26		.txt	text/plain	3115	168	43	11 We hypothesised that COX-2 inhibitors are safe in the treatment of COVID-19, and may be associated with a reduction in adverse outcomes in high-risk older patients with pneumonia, primarily through attenuation of the hyperinflammatory immune response associated with severe disease. In this population at increased risk of severe COVID-19 (≥ 50 years old and with radiographic pneumonia), there was no evidence that COX-2 inhibitor treatment was associated with an increase in adverse outcomes, supporting the use of short duration therapy in COVID-19 for symptom relief and as an anti-pyretic. With the small sample size for IL-6 measurements in the treatment group, these IL-6 data are primarily descriptive and exploratory, and further study is required to establish a clear correlation between COX-2 inhibitor treatment and its impact on IL-6 levels in COVID-19. The dysregulated immune response associated with severe COVID-19 is well characterised, with multiple studies showing elevated serum levels of inflammatory cytokines in patients with severe disease and mortality.	./cache/cord-306072-tfvt6sjq.txt	./txt/cord-306072-tfvt6sjq.txt